Clinical Trials Logo

Filter by:
NCT ID: NCT04410445 Terminated - Melanoma Clinical Trials

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

PIVOT-12
Start date: July 27, 2020
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

NCT ID: NCT04407689 Terminated - COVID-19 Clinical Trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

ILIAD-7-FR
Start date: June 8, 2020
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.

NCT ID: NCT04406766 Terminated - Clinical trials for Parenteral Nutrition, Home

Evaluation of a Connected Parenteral Pump for Patients Treated by Home Parenteral Nutrition (HPN).

SERENE-eNUTRI
Start date: September 28, 2020
Phase: N/A
Study type: Interventional

Patients requiring long-term home parenteral nutrition (HPN) suffer from chronic intestinal insufficiency. The causes of this syndrome can be either anatomical (extensive resection of the small bowel) or functional (occlusion, pseudo-occlusion, malabsorption). Consequences mean that patients are unable to cover their oral energy and / or hydroelectrolytic needs. As a result, these patients survive only through a nutritional support by the venous route (parenteral nutrition). However, this lifesaving therapy requires complex technological nutritional support issues at home, which will influence the personal life of the patients. At home, HPN therapy is performed by nutrition pumps providing a constant flow and able to detect anomalies. In this context, the development of connected systems that allow informations transmission could help patient's caregiving by the different persons involved in his follow-up (prescribing physicians, home support nurses, patients and relatives, manufacturers). The main objective of this study is to evaluate the performance of an end-to-end data transmission chain which integrates a nutrition pump connected to a medical IoT module (developped by Maatel) able to send information to an applicative layer (software interface PatHView2, developped by Orange Labs) via different transmission modes : LoRaWAN (Long Range Wide-area network), BLE (Bluetooth Low Energy), GSM LTE-M (Global System for Mobile Communications, Long Term Evolution - Machine Type Communication).

NCT ID: NCT04404140 Terminated - Clinical trials for Castration-Resistant Prostatic Cancer

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Start date: July 9, 2020
Phase: Phase 1
Study type: Interventional

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort of approximately 38 participants. All participants in this study will continue to be treated until progression of disease, loss of clinical benefit, unacceptable toxicity or withdrawal of consent.

NCT ID: NCT04398667 Terminated - Refractory Epilepsy Clinical Trials

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

Start date: March 14, 2019
Phase:
Study type: Observational

This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review).

NCT ID: NCT04398017 Terminated - Cardiac Diseases Clinical Trials

MEOPA-coupled Hypnosis Versus MEOPA-standard Care in Transesophageal Echocardiography

HYPNETO
Start date: October 14, 2020
Phase: N/A
Study type: Interventional

The primary purpose is to evaluate the impact of hypnosis coupled with MEOPA (Equimolar Mix-ture of Nitrogen Protoxide and Oxygen) on patient comfort when performing transoesophageal echocardiographies. Further studies on the use of MEOPA alone or the technique of hypnosis alone in the context of an TEE, would not be innovative in any way in view of previous studies or already in progress. However, service has led to perform TEEs several times by combining MEOPA and hypnosis. Doctors noted a clear reduction in induction time for hypnosis and satisfaction of the patient and operators. This association technique is very often used in pediatrics. According to one study, it seems that MEOPA increases the threshold of suggestibility and imagination. However suggestion and imagination are two essential notions of the hypnotic technique. To date, doctors have not found any other studies combining MEOPA and hypnosis for adults patients in the context of TEE. This leads to the following hypothesis: Is there a difference for the patient in terms of for the global management of pain and anxiety between an TEE performed under MEOPA with a standard support and TEE under MEOPA coupled with hypnosis with support standard? Secondary purposes are: 1. Compare patients' feelings / opinions: patients who have benefited from hypnosis associated with MEOPA versus patients who have been treated with MEOPA alone. 2. Compare patient stress: patients who have benefited from hypnosis associated with MEOPA versus patients who have benefited from MEOPA alone. 3. Compare the operators' feelings / opinions: procedures that have been performed under hypno-analgesia and MEOPA versus standard procedures under MEOPA alone. 4. Failed the TEE procedure

NCT ID: NCT04393038 Terminated - COVID-19 Clinical Trials

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Mir-Age
Start date: July 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2 (the MiR-AGE study).

NCT ID: NCT04390763 Terminated - Clinical trials for Metastatic Pancreatic Ductal Adenocarcinoma

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

daNIS-1
Start date: October 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in untreated mPDAC.

NCT ID: NCT04390113 Terminated - BK Virus Infection Clinical Trials

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Start date: March 18, 2021
Phase: Phase 3
Study type: Interventional

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).

NCT ID: NCT04385433 Terminated - Breast Cancer Clinical Trials

A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

PRAVAPREV-01
Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

-Interventional trials aim at preventing severe RIF occurrence in BC patients selected by individual radiosensitivity: PRAVAPREV-01 will be the first interventional double blind trial that will offer a personalised strategy to breast cancer patients who will be treated with adjuvant RT after breast conserving surgery: - By assessing individual risk of severe RIF development - By offering a statin targeted therapy to the high-risk patients identified.